Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01393470
Registration number
NCT01393470
Ethics application status
Date submitted
5/07/2011
Date registered
13/07/2011
Date last updated
15/05/2014
Titles & IDs
Public title
Evaluation of Long-term HPV Vaccine Efficacy
Query!
Scientific title
A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland
Query!
Secondary ID [1]
0
0
115006 (HPV-027)
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Uterine Cervical Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Cancer
0
0
0
0
Query!
Cervical (cervix)
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Treatment: Surgery - Screening for cervical cancer
Cohort A (Trial Cohort, Vaccinated during HPV-008) - Cohort A subjects were previously enrolled in the HPV-008 study, and have received at least 1 dose of the HPV vaccine.
Cohort A subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.
Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.
Cohort B1 + B2 - Cohort B1 subjects were previously enrolled in the HPV-008 study and received at least 1 dose of HPV vaccine as cross-over vaccination at the end of the HPV-008 study.
Cohort B1 subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.
Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.
Cohort B2 (Trial Cohort, Non-Vaccinated)
Cohort C (Referent Cohort, Non-Vaccinated) - Cohort C subjects have not participated in the HPV-008 study but have been enrolled in the Referent Cohort.
Cohort C subjects have not received any HPV vaccination (neither Cervarix, nor Gardasil, nor any experimental HPV vaccine).
Cohort C subjects are partially matched to HPV-008 in terms of the geographical recruitment area.
Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.
Treatment: Surgery: Screening for cervical cancer
Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
Query!
Intervention code [1]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Occurrence of intraepithelial neoplasia grade 3 or worse (CIN3+). including CIN3, cervical cancer (squamous cell carcinoma or adenocarcinoma).
Query!
Assessment method [1]
0
0
To estimate the long-term vaccine efficacy by comparing the incidence rate of cervical cancers and pre-cancerous lesions (CIN3+) in Cohort A vs. Cohort C.
Query!
Timepoint [1]
0
0
The time frame is up to 15 years (for the interim analyses: 4, 7 and 10 years). (Start and end of passive follow-up, Cohorts A and B: 01.01.2010 - 31.12. 2024; Cohorts C1 and C2: 01.10.2007/01.10.2008 - 30.09.2021/30.09.2023.)
Query!
Secondary outcome [1]
0
0
Occurrence of potentially HPV related non-cervical cancers or pre cancerous lesions, including but not limited to the occurrence of vulvar intraepithelial neoplasia and vaginal intraepithelial neoplasia.
Query!
Assessment method [1]
0
0
To estimate the efficacy of HPV-16/18 vaccine against non-cervical cancers by comparing the incidence of non-cervical cancers in Cohort A vs. Cohort C.
Query!
Timepoint [1]
0
0
The time frame for the objectives of the study is up to 15 years. (Start and end of passive follow-up, Cohorts A and B: 01.01.2010 - 31.12. 2024; Cohorts C1 and C2: 01.10.2007/01.10.2008 - 30.09.2021/30.09.2023.)
Query!
Eligibility
Key inclusion criteria
- Trial Cohort (16-17 years at baseline) - the cohort of Finnish subjects who
participated in the GSK Biologicals' HPV-008 trial (NCT00122681):
- Cohort A: subjects who received HPV-16/18 L1 VLP AS04 vaccine between May 2004 and May
2005.
- Cohort B: subjects who received the Hepatitis A control vaccine. All subjects were
offered the HPV-16/18 L1 VLP AS04 vaccine at the end of the study (age 21-22).
- Cohort B1: subjects who received the Hepatitis A control vaccine and then received
cross-over HPV vaccination at HPV-008 study end.
- Cohort B2: subjects who received the Hepatitis A control vaccine and who did not
receive cross-over HPV vaccination at HPV-008 study end.
- Referent cohort (18-19 years at baseline):
- Cohort C: A population-based reference cohort of female subjects from Finland who have
not been exposed to any HPV vaccine enrolled in this study in May 2005, immediately
after recruitment of the HPV-008 clinical trial subjects had been stopped
(approximately 9,000 subjects).
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
19
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Trial Cohort (Cohort A and B): Previous or planned administration of an HPV vaccine
not foreseen by the HPV-008 study protocol or any HPV-008 extension study protocol
(Gardasil or any experimental HPV vaccine).
- Referent cohort (Cohort C): Previous or planned administration of an HPV vaccine
(Cervarix, Gardasil or any experimental HPV vaccine).
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2024
Query!
Actual
Query!
Sample size
Target
10000
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Finland
Query!
State/province [1]
0
0
Helsinki
Query!
Country [2]
0
0
Finland
Query!
State/province [2]
0
0
Jyväskylä
Query!
Country [3]
0
0
Finland
Query!
State/province [3]
0
0
Kotka
Query!
Country [4]
0
0
Finland
Query!
State/province [4]
0
0
Kouvola
Query!
Country [5]
0
0
Finland
Query!
State/province [5]
0
0
Kuopio
Query!
Country [6]
0
0
Finland
Query!
State/province [6]
0
0
Lahti
Query!
Country [7]
0
0
Finland
Query!
State/province [7]
0
0
Lappeenranta
Query!
Country [8]
0
0
Finland
Query!
State/province [8]
0
0
Mikkeli
Query!
Country [9]
0
0
Finland
Query!
State/province [9]
0
0
Oulu
Query!
Country [10]
0
0
Finland
Query!
State/province [10]
0
0
Pori
Query!
Country [11]
0
0
Finland
Query!
State/province [11]
0
0
Rauma
Query!
Country [12]
0
0
Finland
Query!
State/province [12]
0
0
Seinäjoki
Query!
Country [13]
0
0
Finland
Query!
State/province [13]
0
0
Tampere
Query!
Country [14]
0
0
Finland
Query!
State/province [14]
0
0
Turku
Query!
Country [15]
0
0
Finland
Query!
State/province [15]
0
0
Vaasa
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Tampere University
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
FinnMedi Oy
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/Industry
Query!
Name [2]
0
0
GlaxoSmithKline
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Summary
For ethical and practical reasons pre-licensure clinical efficacy phase III trials for GSK
Biologicals' HPV-16/18 LI VLP AS04 vaccine used cervical intraepithelial grade 2 and above
(CIN2+) lesions as surrogate efficacy endpoint for cervical cancer. The long-term impact of
HPV vaccination on cervical cancer as well as other HPV-related non- cervical cancers is,
however, an area warranting further exploration in the post-licensure setting. Results of the
multinational phase III trial demonstrated high vaccine efficacy against CIN2+ associated
with HPV-16 and/or HPV-18, significant vaccine efficacy against CIN2+ and CIN3+ irrespective
of HPV type in the lesion as well as evidence of protection against CIN2+ associated with HPV
types 31 and 45 [Paavonen, et al. 2009]. Over time, vaccinated cohorts should benefit from a
substantial reduction in the incidence of cervical cancer considering impact on oncogenic
non-vaccine HPV types. This long-term study is conducted to evaluate the long-term impact of
GSK Biologicals' HPV-16/18 vaccine on the occurrence of cervical pre-cancerous lesions and
cervical cancer with the following objectives:
- To assess the long-term efficacy of the HPV-16/18 L1 VLP AS04 vaccine on the occurrence
of cervical cancer including its immediate precursors (CIN3+): cervical intraepithelial
neoplasia grade 3 (CIN3) and adenocarcinoma in situ (AIS) by comparing cohorts A and C
(see below).
- To assess the efficacy of HPV-16/18 L1 VLP AS04 vaccine on the occurrence of the
following potentially HPV related non-cervical cancers such as vulvar intraepithelial
neoplasia, vaginal intraepithelial neoplasia, anogenital neoplasia and oropharyngeal
neoplasia by comparing cohorts A and C (see below)
- To assess as an explanatory objective the occurrence of CIN3+ breakthrough cases
associated with HPV-16 or HPV-18 infection in subjects vaccinated with HPV-16/18 L1 VLP
AS04 vaccine by close surveillance of cohorts and cross vaccinated cohort B (see below)
This prospective, observational cohort study is undertaken in originally 16-17 year-old
Finnish females who have participated in the GSK Biologicals' HPV-008 trial (NCT00122681)
with regular clinical follow-up, and can be divided in Cohort A: Female subjects from Finland
who received HPV-16/18 L1 VLP AS04 vaccine in the HPV-008 study between May 2004 and May 2005
(N=2409), and Cohort B: Female subjects from Finland who received the Hepatitis A control
vaccine in the HPV-008 study (N=2399). All subjects were offered the HPV-16/18 L1 VLP AS04
vaccine or screening for cervical cancer at the end of the study (age 21-22): 50% of the
subjects, chose not to take cross-over HPV vaccination at HPV-008 study end. Referent Cohort
C: A population-based reference cohort of female subjects from Finland who have not been
exposed to any HPV vaccine (either during a HPV vaccine trial, or commercially available
vaccine; i.e. Cervarix or Gardasil), enrolled in this study in May - September 2003 or May -
September 2005, altogether 15536 subjects).
Prospective data collection will start at the HPV screening invitation for each subject in
2013. Several analyses are planned including an analysis at 8 years post-completion of the
HPV-008 study (by 2020) and will provide a total evaluation time of approximately 15 years
since first vaccination in the Cohort A.
The study is self-contained for the primary and secondary endpoints. Data from the HPV-008
trial will be used to address exploratory objectives mentioned above. Data collection will be
performed using the databases from the University of Tampere.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01393470
Query!
Trial related presentations / publications
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum In: Lancet. 2010 Sep 25;376(9746):1054.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007 Jun 30;369(9580):2161-2170. doi: 10.1016/S0140-6736(07)60946-5. Erratum In: Lancet. 2007 Oct 20;370(9596):1414.
Lehtinen M, Idanpaan-Heikkila I, Lunnas T, Palmroth J, Barr E, Cacciatore R, Isaksson R, Kekki M, Koskela P, Kosunen E, Kuortti M, Lahti L, Liljamo T, Luostarinen T, Apter D, Pukkala E, Paavonen J. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS. 2006 Apr;17(4):237-46. doi: 10.1258/095646206776253453.
Lehtinen M, Paavonen J. Effectiveness of preventive human papillomavirus vaccination. Int J STD AIDS. 2003 Dec;14(12):787-92. doi: 10.1258/095646203322556084.
Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL, Kyha-Osterlund L, Lunnas T, Luostarinen T, Niemi L, Palmroth J, Petaja T, Rekonen S, Salmivesi S, Siitari-Mattila M, Svartsjo S, Tuomivaara L, Vilkki M, Pukkala E, Paavonen J. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS. 2006 Aug;17(8):517-21. doi: 10.1258/095646206778145550.
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Matti Lehtinen, M.D., Ph.D.
Query!
Address
0
0
Tampere University
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01393470
Download to PDF